Abstract
A series of 191 female breast carcinomas (with long-term follow-up) were analysed immunohistochemically (with a monoclonal MIB1 antibody) for Ki-67 (a proliferation marker) expression with special reference to well-established prognostic factors and patient survival. Expression of Ki-67 was directly related to the S-phase fraction (P<0.0001), the volume-corrected mitotic index (P<0.0001), histological grade (P<0.0001), the apoptotic index (P<0.0001), oestrogen and progesterose receptor content (P<0.0001 for both) and p53 accumulation (P=0.001). No correlation was found between Ki-67 expression and lymph node status (P=0.25), metastasis at operation (n=0.81) or tumour size (n=0.38). The proliferation rate, as measured by image analysis of Ki-67 expression, predicted survival in the entire cohort (P=0.001) and in axillary-lymph-node-negative (ANN) patients (P=0.003). The difference in recurrence-free survival between the high- and low-expression groups was greatest in ANN tumours, 40% (P=0.008). In axillary-lymph-node-positive tumours, the Ki-67 expression was not significantly related to recurrence-free survival (P=0.723). The results of multivariate survival analysis showed that tumour size, axillary lymph node status, and mitotic index were independent prognostic factors in the entire series whereas, in ANN cases, tumour size and Ki-67 labelling were independent prognostic factors. These findings imply that Ki-67 expression could be an important prognostic determinant in breast cancer. Because of the evident loss of the predictive power of tumour size in the 1990s, the prognostic value of Ki-67 expression may even be accentuated in the currently diagnosed small breast carcinomas.
Similar content being viewed by others
Abbreviations
- M/V :
-
index the volume-corrected mitotic index
- ANN :
-
axillary lymph node negative
- ANP :
-
axillary lymph node positive
References
Aaltomaa S, Lipponen P, Eskelimen M, Kosma VM, Marin S, Alhava E, Syrjanen K (1991) Prognostic scores combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer. Int J Cancer 49:886–892
Aaltomaa S, Lipponen P, Eskelinen M, Kosma VM, Marin S, Alhava E Syrjanen K (1992) Mitotic indexes as prognostic predictors in female breast cancer. J Cancer Res Clin Oncol 118:75–81
Beck T, Weller EE, Brumm C, Wilkens C, Knapstein PG (1995) Usefullness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognostic parameters and with the proliferation marker, MIB-1. Gynecol Oncol 57:96–104.
Bloom HJG, Richardson WW (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359–377
Bouzubar N, Walker KJ, Griffiths K, Ellis IO, Elston CW, Robertson JF, Blamey RW, Nicholson RI (1989) Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer 59:943–947
Brown DC, Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489–503
Cattoretti G, Becker MH, Key G, Duchrow M, Schluter C, Galle J, Gerdes J (1992) Monoclonal antibodies against recombinant parts of the Ki-67 antigen(MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168:357–363
Chauvel P, Courdi A, Gioanni J, Vallicinoi J, Santini J, Demard F (1989) The labelling index: a prognostic factor in head and neck carcinoma. Radiother Oncol 14:231–237
Eskelinen M, Lipponen P, Papinaho S, Aaltomaa S, Kosma VM, Klemi P, Syrjanen K (1992) DNA flow cytometry, nuclear morphometry, mitotic indices and steroid receptors as independent prognostic factors in female breast cancer. Int J Cancer 51:555–561
Gasparini G, Boracchi P, Verderio P, Bevilacqua P (1994) Cell kinetics in human brest cancer: comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 57:822–829
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119:493–501
Huovinen R, Collany (1994) Cell loss in dimethylbenz(a)anthraceneinduced rat mammary carcinoma treated with toremifene and ovariectomy. Tumor Biol 15:345–353
Isola J, Visakorpi T, Holli K, Kallioniemi OP (1992) Association of overexpression of tumour suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109–1114
Jensen EV (1991) Steroid hormone receptors. Curr Top Pathol 83:365–431
Kennedy JC, Badawy N, el, DeRose PB, Cohen C (1992) Comparison of cell prolifration in breast carcinoma using image analysis (Ki-67) and flow cytometric systems. Anal Quant Cytol Histol 14:304–311
Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73:2013–2026
Lee E, Lesu M (1972) A computer program for comparing k samples with right censored data. Comput Prog Biomed 2:315–320
Liotta LA (1992) Cancer cell invasion and metastasis. Sci Am 266:54–59, 62–63
Martinazzi M, Crivelli F, Zampatti C, Martinazzi S (1993) Relationship between p53 expression and other progonostic factors in human breast carcinoma. An immunohistochemical study. Am J Clin Pathol 100:213–217
Pavelic ZP, Pavelic L, Lower EE, Gapany M, Gapany S, Barker EA Preisler HD (1992)c-myc, c-erb B-2, and Ki-67 expression in normal breast tissue and in invasive and noninvassive breast carcinoma. Cancer Res 52:2597–2602
Pietiläinen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K (1995) Expression of p53 protein has no independent prognostic value in breast cancer. J Pathol 177:225–232
Pinder SE, Wencyk P, Sibbering DM, Bell JA, Elston CW, Nicholson R, Robertson JF, Blamey RW Ellis IO (1995) Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer 71:146–149
Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, von Smitten K (1993) Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68:579–583
Rudas M, Gnant MF, Mittlbock M, Neumayer R, Kummer A, Jakesz R, Reiner G, Reiner A (1994) Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 32:165–175
Schulte Hermann R, Grasl Kraupp B, Bursch W (1994) Tumour development and apoptosis. Int Arch Allergy Immunol 105:363–367
Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965–970
Steller H (1995) Mechanisms and genes of cellular suicide. Science 267:1145–1449
Vihko R, Jänne O, Kontula K, Syrjälä P (1980) Female sex steroid reseptor status in primary and metastatic breast carcinoma and its relationship to serum steroid and peptide hormone levels. Int J Can 26:13–21
Walker NI, Harmon BV, Gobe GC, Kerr JFR (1988) Patterns of cell death. Methods Achiev Exp Pathol 13:18–54
Weinder N, Moore DHI, Vartarian R (1994) Correlation of Ki-67 antigen expression with mitotic figure index and tumour grade in breast carcinoma using the novel “paraffin”-reactive MIBI antibody. Hum Pathol 25:337–342
WHO (1981) Histological typing of breast tumours. In: International histological classification of tumours. 2, 2nd ed. World Health Organization, Geneva
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pietiläinen, T., Lipponen, P., Aaltomaa, S. et al. The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol 122, 687–692 (1996). https://doi.org/10.1007/BF01209033
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01209033